Compare Cytokinetics Inc (CYTK) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Essex Property Trust, Inc. — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Essex Property Trust, Inc. trades at $297.8 (market cap $19.16B). The key difference: Essex Property Trust, Inc. is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.47% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | ESS | |
|---|---|---|
Market Cap | $11.12B | $19.16B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $298.33 |
52-Week Low | $33.23 | $239.61 |
Enterprise Value | $11.59B | $25.88B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
ESS trades at $297.48, up 1.34% today, near its consensus price target of $294.25. The stock shows bullish technical momentum with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index. Fundamentals remain solid with $1.89B revenue and a 30.03% net income margin in 2025.
Outlook is cautiously optimistic given analyst consensus leaning toward Hold (52.17%) despite recent beats. Key opportunities include AI-driven rental demand in West Coast markets and a sustainable dividend. Risks involve high debt levels (debt-to-asset ratio of 51.92% in 2024) and potential economic sensitivity. The stock offers moderate upside if earnings momentum continues but requires monitoring of leverage and regional market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
